Physician profile
Michael Ayzin
NPI 1750308292
$6,874.14
in general payments reported to CMS, 2019-2025
9 companies · $445 in 2025
The $445 reported for 2025 was more than what 89% of General Practice (Dentist) providers received nationally (typical 2025 total: $74.60).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,201 · 2020: $206 · 2021: $300 · 2022: $623 · 2023: $431 · 2024: $668 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135 · Consulting Fee: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.06 |
| Consulting Fee | $410.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biolase, INC. | $4,144.25 | 2019 | |
| Align Technology, INC. | $1,462.36 | 2019-2025 | Invisalign, Itero Element 5d Plus Lite, Invisalign System - Moderate |
| Zimvie INC. | $602.89 | 2023-2025 | |
| Biohorizons Implant Systems INC. | $334.44 | 2020-2022 | |
| Nobel Biocare USA | $130.25 | 2023 | Nobelactive |
| Orapharma, A Division of Bausch Health US, LLC | $109.86 | 2022-2025 | Arestin |
| Solventum Corporation | $45.38 | 2025 | Clarity Aligners, 3m Relyx, Clinpro 5000 |
| Straumann USA LLC | $29.94 | 2020-2021 | |
| Zest Holdings, LLC | $14.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ayzin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.